medRxiv preprint doi: https://doi.org/10.1101/2024.03.22.24304609; this version posted March 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# Illicit Fentanyl Use Independently Predicts HCV Seroconversion Among a Cohort of People Who Inject Drugs in Tijuana and San Diego

3

7

Joseph R Friedman<sup>1\*</sup>, Daniela Abramovitz<sup>2</sup>, Britt Skaathun<sup>2</sup>, Gudelia Rangel<sup>3,4</sup>, Alicia Harvey-Vera<sup>2</sup>,
Carlos F Vera<sup>2,4</sup>, Irina Artamonova<sup>2</sup>, Sheryl Muñoz<sup>4,5</sup>, Natasha K Martin<sup>2</sup>, William H Eger<sup>2,6</sup>, Katie
Bailey<sup>2</sup>, Bo-Shan Go<sup>7</sup>, Philippe Bourgois<sup>1</sup>, Steffanie A Strathdee<sup>2\*</sup>

- 8 <sup>1</sup>Center for Social Medicine and Humanities, UCLA<sup>2</sup> Department of Medicine, University of California,
- 9 San Diego<sup>3</sup> Colegio de la Frontera Norte Mexico, <sup>4</sup>Comisión de Salud Fronteriza México-Estados
- 10 Unidos, Sección mexicana<sup>5</sup>Universidad Xochicalco, Escuela de Medicina, Campus Tijuana<sup>6</sup> School of
- 11 Social Work, San Diego State University <sup>7</sup>University of Amsterdam Medical Center.
- 12

14

- 13 \*Correspondence to: Joseph.Robert.Friedman@gmail.com and sstrathdee@health.ucsd.edu
- 15 Summary (40 words maximum): In this cohort study of people who inject drugs in Tijuana, Mexico,
- and San Diego, California, fentanyl use was independently associated with HCV seroconversion.
- 17 Tailored treatment and prevention efforts are needed for patients using fentanyl to minimize blood-
- 18 borne infections.
- 19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 20 Abstract

### 21 Background:

- 22 Illicitly manufactured fentanyl (IMF) increases overdose mortality, but its role in infectious disease
- 23 transmission is unknown. We examined whether IMF use predicts HCV and HIV incidence among a
- 24 cohort of people who inject drugs (PWID) in San Diego, CA and Tijuana, Mexico.
- 25
- 26 Methods:
- 27 PWID were recruited into a prospective cohort in two waves during 2020-2022, undergoing semi-
- 28 annual interviewer-administered surveys, HIV and HCV serology through February 2024. Cox
- 29 regression was conducted to examine predictors of seroconversion considering self-reported IMF
- 30 use as a fixed or lagged, time-dependent covariate.
- 31

### 32 Results:

- 33 Of 398 PWID at baseline, 67% resided in San Diego, 70% were male, median age was 43, 42%
- 34 reported receptive needle sharing and 25% reported using IMF. Participants contributed a median of
- 35 6 semi-annual study visits (IQR:4-6). HCV incidence was 14.26 per 100 person-years (95% CI: 11.49-
- 36 17.02), and HIV incidence was 1.29 (1.00-2.28). IMF was associated with HCV seroconversion, with a
- 37 univariable hazard ratio (HR) of 1.68 (95%CI: 1.12-2.53) which remained significant in multivariable
- 38 models (adjHR1.54; 95%CI:1.01-2.34). The direction of the relationship with HIV was similar, albeit
- 39 not significant, with an HR of 2.53 (0.7-9.15).
- 40

### 41 **Conclusion**:

- 42 We document a novel association between IMF and HCV seroconversion among PWID in Tijuana-San
- 43 Diego. There was insufficient power to detect if a similar relationship held for HIV. IMF's short half-
- 44 life may destabilize PWID— increasing the need for repeat dosing and sharing smoking materials and
- 45 syringes. Tailoring medication dosing for opioid use disorder and new preventative care approaches
- 46 may reduce HCV transmission in the fentanyl era.

### 47 Main Text

48

### 49 Introduction

50

51 Illicitly manufactured fentanyls (IMF) have transformed the risk environment for people who use

drugs (PWUD) in North America [1]. Having outcompeted heroin for dominance in the illicit opioid
 market, IMF have caused dramatic increases in overdose mortality over the past decade [2]. Given

54 their high potency, seemingly small fluctuations in product quality can result in large increases in

- 55 overdose risk [1].
- 56

IMF also have additional properties that may elevate infectious disease transmission risk, including
shorter half-lives and more powerful euphoric effects relative to heroin and other opioids [3]. This
has been associated with increased injection frequency to prevent withdrawal symptoms and
achieve sustained effects [4]. IMF use has consequently been associated with higher-risk injection

61 practices compared to heroin use, such as sharing syringes [5–7]. Literature describing implications

- 62 of IMF use, including drug preparation and administration practices [8] and behavioral aspects
- 63 (including the pursuit of euphoria) [9], suggest that there may be an important—albeit not currently
- 64 described—link between IMF use and human immunodeficiency virus (HIV) and hepatitis C virus
- 65 (HCV). Sharply rising HCV incidence among young people over the past two decades has been linked

to increasing rates of injection drug use nationally, although the particular role of fentanyl has not

- 67 been determined [10–12].
- 68

69 We examined whether IMF use predicts HIV and HCV incidence among a longitudinal cohort of

70 people who inject drugs (PWID) in the US-Mexico border region of Tijuana, Mexico, and San Diego,

- 71 California, a region with a large population of vulnerable PWID who experience a high burden of
- 72 HCV, and where IMF has broadly overtaken the drug supply.
- 73

75

### 74 Methods

### 76 Study Design and Participants

Participants were drawn from the *La Frontera* study, which is a prospective cohort of PWID in
Tijuana, Mexico and San Diego, California, focused on HIV, HCV and overdose. Eligible participants
were age 18+, reported injection drug use in the past month (confirmed by inspection of injection
marks), spoke English or Spanish, and resided in San Diego or Tijuana.

81

Data were collected by trained bilingual interviewers, using a mobile outreach van targeting areas
with concentrated injection drug use. Recruitment occurred in two waves from October 2020October 2021 and February 2022-June 2022 (Supplemental Table 1). The parent study aimed to
examine the role of cross-border mobility on infectious disease transmission and thus specifically
recruited half of the San Diego resident sample to be individuals who reported crossing the border
to use drugs in Tijuana in recruitment wave one. All wave two participants were San Diego residents.

- 88 Participants underwent semi-annual interviewer-administered surveys, as well as HIV and HCV
- 89 serology, through February 2024 and received \$20 USD for each study visit. Study activities were
- 90 approved by Institutional Review Boards at the University of California San Diego and Universidad
- 91 Xochicalco in Tijuana. All participants provided written informed consent.
- 92

93 For this study, 720 participants (612 in wave one and 108 in wave two) were initially assessed. To

- assess HCV incidence, 280 individuals testing HCV-seropositive at baseline were excluded as well as
- two individuals with missing HCV serology. Of the 438 who tested HCV-seronegative at baseline, 398
- 96 (90.9%) completed at least one follow-up visit and comprised the analytic sample. Of 40 individuals

- 97 lost to follow-up, 10 (25%) were reported as deceased, of which six were confirmed. Similarly, 35
- 98 participants who tested HIV-seropositive at baseline were excluded from HIV incidence calculations.
- 99

#### 100 **HCV and HIV Serology**

- 101 At each semi-annual study visit, HCV and HIV serostatus were assessed by rapid immunoassays
- 102 based on blood samples [13,14] that were approved for use in the US or Mexico. Participants in San
- 103 Diego were first administered a Medmira® Miriad combined HIV/HCV immunoassay (sensitivity
- 104 [se]:79%-88%, specificity[sp]:100%). For any participants testing seropositive, a second line of rapid
- 105 tests were conducted with Orasure® HIV (se:99.3%-100%,sp:100%) and HCV (se: 97%-98%,sp:100%).
- 106 In Tijuana, Accutrak<sup>®</sup> HIV (se: 100%, sp: 100%) and HCV (se:100%, sp: 97-99%) tests were used for all
- 107 participants. Participants with a reactive first rapid test underwent a second line of rapid testing with
- 108 Intec® for HIV and Quality® for HCV, respectively. All samples that were reactive at the second line of
- 109 rapid testing were sent to UCSD Laboratories for ELISA-based confirmatory testing.
- 110

#### 111 **Survey Measures**

- 112 Sociodemographic and behavioral characteristics assessed at baseline and 6-month intervals
- 113 included age, sex assigned at birth, ethnicity, city of residence, housing status, substance use
- 114 behaviors, and others. For each 6-month period, we assessed if participants had knowingly used
- 115 fentanyl, heroin, methamphetamine, or cocaine via self-report. For the purposes of this study,
- 116 fentanyl use was operationalized as both a fixed baseline characteristic and a time-varying
- 117 characteristic (with a 12-month lag) to reflect the temporal association between fentanyl use and
- 118 subsequent increases in infectious disease transmission risks reported in the literature[5].
- 119

#### 120 **Statistical Analysis**

- 121 We summarized baseline characteristics by HCV incidence status and calculated overall HIV and HCV
- 122 incidence density rates per 100 person-years, as well as rates stratified by key variables chosen a
- 123 priori, including 95% confidence intervals calculated assuming a Poisson distribution.
- 124
- 125 Limited statistical power precluded multivariable analyses where HIV seroconversion was the
- 126 outcome. For HCV seroconversion, univariable and multivariable fixed and time-dependent Cox
- 127 regression models were employed to assess the relationship between fentanyl use and HCV
- 128 seroconversion, as well as other potential confounders and predictors based on subject-matter
- 129 knowledge and previous literature—including substances used, injection behaviors known to
- 130 increase HCV transmission risk, and key sociodemographic factors[5,6]. We employed a shared
- 131 frailty (random effect) based on recruitment wave to control for potential intra-group correlations
- 132 induced by group-specific recruitment criteria (i.e., residency and cross-border drug use) as well as
- 133 differences in recruitment time between the two waves which caused time spent at risk to be
- 134 dependent on recruitment wave [15]. All predictors of interest were first assessed in univariable
- 135 regressions as fixed, non-time-varying predictors based on values at baseline. Next, we examined
- 136 variables that yielded p-values <0.20 in the first round of models, and for which repeated measures
- 137 were available, as time-varying predictors. Of those, the variable form that yielded a higher marginal
- 138 log-likelihood was retained for the univariable and multivariable regression models. All variables
- 139 associated with time-to-HCV seroconversion in univariable analyses at  $p \le 0.10$  were considered
- 140 candidates for inclusion in multivariable models, controlling for age and sex (which were chosen as a
- 141 priori control variables). Only variables that yielded a  $p \le 0.05$  in an initial multivariable model were 142 retained in the final multivariable model. The final model was checked for multi-collinearity,
- 143 interactions between covariates, proportionality of hazards, and linear relationships.
- 144

145 To assess the potential for retention bias, participants who were included in this analysis were

- 146 compared to participants who were lost to follow-up with respect to key baseline characteristics
- 147 (Supplemental Table 2). All statistical analyses were performed using SAS software version 9.4 (SAS,

- 148 Cary, NC), and graphics were made using R version 4.3.1. (See supplemental methods for additional 149 analytic details).
- 150

#### 151 Results

152 153

154

155

156

157

158

Participant characteristics, stratified by HCV seroconversion status, are shown in Table 1 for the 398 participants in the analytic sample (i.e., n=102 individuals who seroconverted and n=296 individuals who remained HCV seronegative during follow-up). At baseline, 67.3% resided in San Diego; 69.8% were male; median age was 42.5 years; 66.8% identified as Hispanic, Latinx or Mexican; and median years of schooling was 10.5 (i.e., some secondary school/high school) [Interguartile range [IQR]: 7.0-12.0]. Baseline characteristics revealed a highly vulnerable population, with 41.5% experiencing homelessness in the past 6 months.

159 160

161 Polysubstance use was common; the most commonly used substances were methamphetamine

- 162 (83.7%), heroin (80.2%), cannabis (53.8%) and fentanyl (25.4%). Forty-two percent reported
- 163 receptive needle sharing at baseline. The median number of average injections per day was 2.5 (IQR:
- 164 0.3-4.0). Addiction-related healthcare engagement was poor, with only 6.3% of participants
- 165 reporting current enrollment in a methadone, buprenorphine or other addiction treatment program.
- 166 Participants contributed a median of six semi-annual study visits (IQR:4-6).
- 167

168 We observed 10 HIV seroconversions during the study period (Table 2), resulting in an incidence rate 169 of 1.29 per 100 person-years (95%CI: 1.00-2.28). Among people reporting fentanyl use, HIV

- 170 incidence was 2.28 per 100 person-years (95% confidence interval[CI]: 0.05-4.50) compared to 1.00
- 171 (95%CI: 0.20-1.80) among those not reporting fentanyl use. The univariable HR for the association
- 172 between fentanyl use and HIV seroconversion was 2.53 (95%CI: 0.7-9.15).
- 173

174 HCV incidence over the 36-month study period was 14.26 per 100 person-years (95% CI: 11.49-175 17.02). Among individuals who reported using fentanyl at baseline, HCV incidence was 23.7 per 100 176 person-years (95%CI: 15.9-31.6) compared to 11.8 per 100 person-years (95%CI: 8.97-14.63) among 177 those not reporting fentanyl use (Figure 1). Fentanyl use, both at baseline and as a time-varying 178 predictor (lagged by 12 months) was significantly associated with HCV seroconversion. As a time-179 varying predictor, fentanyl use had a univariable hazard ratio (HR) of 1.68 (95%CI: 1.12-2.53) (Figure 180 2) and remained independently associated with HCV seroconversion after controlling for receptive 181 needle sharing, sex, and age (adjHR1.54; 95%CI:1.01-2.33). Fentanyl use at baseline was also 182 significantly associated with HCV seroconversion, with a similar magnitude to the time-varying 183 variable (see supplemental table 5). Adjusting for city of residence or cross-border mobility did not 184 appreciably affect parameter estimates.

185

186 Individuals who practiced receptive needle sharing at baseline had an HCV incidence rate of 15.9 per 187 100 person-years (95%CI: 11.5-20.4) compared to 13.0 per 100 person-years among individuals who 188 did not practice receptive needle sharing (95%CI: 9.5-16.5). In univariable models, as a time-varying 189 predictor, receptive needle sharing was associated with a HR of 1.76 (95%CI: 1.17, 2.67), which

- 190 remained significant in the multivariable model (adjHR: 1.75; 95%CI: 1.15, 2.65).
- 191

192 Among individuals experiencing homelessness at baseline, HCV incidence was 18.5 per 100 person-193 years (95%CI: 13.3-23.7) compared to 11.76 per 100-person years among those not experiencing 194 homelessness (95%CI: 8.6-14.93). Unhoused status was associated with a univariable HR of 1.5 195 (95%CI: 1.0, 2.2) but its marginal association precluded us from including it in multivariable models.

- 196
- 197 Males consistently showed a higher risk of HCV seroconversion than females, with an incidence rate 198 of 16.47 per 100 person-years (95%CI: 12.8-20.1) compared to 9.75 for females (95%CI: 5.77-13.74).

199 Male sex had an unadjusted HR of 1.68 (95%CI: 1.05-2.68) and an adjusted hazard ratio of 1.66 200 (95%CI: 1.04-2.66) for HCV seroconversion. No significant differences were found for age or city of 201 residence.

202

#### 203 Discussion

204 We document a novel association between IMF use and HCV seroconversion among PWID in 205 Tijuana-San Diego. Although IMF have drastically transformed health risks for PWID, most research 206 has focused on increases in fatal overdoses [1]. Less is known about the effects of the broad 207 transition to IMF on HIV and HCV transmission. Leveraging a prospective cohort design and 208 employing street outreach techniques to reach clandestine populations, we found a robust 209 association between IMF use and HCV seroconversion. These findings suggest that dramatic 210 increases in IMF use in North America since 2013 may represent a key, albeit understudied driver of 211 contemporaneous increases in HCV incidence [11]. Given the recent White House HCV elimination 212 plan [16], our findings suggest IMF-specific risk patterns may warrant further study to guide the 213 implementation of the nation's renewed efforts to reduce the burden of HCV. Although the direction 214 and magnitude of the association between IMF use and HIV seroconversion was similar to that of 215 HCV, the small number of HIV seroconversions precluded our ability to examine this relationship

- 216 controlling for other covariates.
- 217

218 More research is needed to understand the mechanisms that may be underpinning the relationship 219 between IMF use and infectious disease transmission. The shorter half-life of most IMF analogues is 220 likely playing a key role. Qualitative and ethnographic data can help us understand the impact of this 221 shift. Compared to the longer half-life of heroin, IMF require much more frequent dosing to prevent 222 withdrawal symptoms, which decreases individuals' ability to work a complete shift at their place of 223 employment, sleep through the night, or conduct other aspects of life without continuous 224 interruptions to use IMF [4]. This is also a frequently stated reason why PWUD seek to augment IMF 225 with other substances, such as methamphetamine, benzodiazepines, non-IMF opioids such as 226 nitazenes, cannabinoids, and xylazine to extend the subjective duration of effect [4,17]. These 227 properties may account for the strong association between IMF and increased injection frequency, 228 as well as syringe sharing that has been reported previously [5–7]. However, IMF remained 229 significantly associated with HCV seroconversion even after accounting for receptive syringe sharing, 230 suggesting that there may be additional effects warranting consideration in understanding the 231 causal mechanism. It is possible that IMF's overall destabilizing effect on the lives of PWID and 232 associated polysubstance use may induce turbulent life circumstances, decreasing their engagement 233 in health and preventative services and predisposing them to behaviors that increase their 234 vulnerability to HCV infection.

235

236 An important contextual factor is the extreme vulnerability of PWID in the study region, especially in 237 Tijuana where HCV prevalence among PWID is higher than in San Diego[18]. Social vulnerabilities 238 represent critical drivers of HCV and HIV risk[19]. Previous studies have shown that a critical factor 239 driving PWID to share syringes and preparation materials is a limited ability to carry paraphernalia 240 without risking police surveillance, violence, and incarceration [20]. Municipal police have 241 historically created challenging circumstances in Tijuana that limit PWID in their ability to carry 242 sterile syringes [20,21]. Similar problems have also been noted in parts of California [22]. There is 243 also a dearth of harm reduction and other services for PWID available in Tijuana, especially given 244 recent withdrawals of governmental funding for the civil sector [21]. Harm reduction services in San 245 Diego were also relatively limited earlier in the study period, due to the COVID-19 pandemic [28]; 246 however, we found no difference in the weekly rates of interviews conducted inside vs. outside 247 COVID-19 restrictive periods.

248

249 The relationship between IMF and HCV raises important implications for treatment and prevention 250 efforts among PWID to prevent further infectious disease transmission. For instance, tailoring dosing 251 of medications for opioid use disorder (MOUD), to respond to the unique pressures of IMF, will be 252 important for reducing HCV transmission risks, as MOUD is known to reduce transmission risk[23]. 253 The lipophilic nature of IMF has complicated buprenorphine induction, making precipitated 254 withdrawal much more likely. However, novel approaches including microinduction (small 255 buprenorphine doses scaled up as IMF are tapered), macroinduction (large starting doses of 256 buprenorphine), and bridging to buprenorphine with short-acting opioids, all offer promising 257 avenues to stabilize patients withdrawing from IMF [24–26]. Treatment modalities for people using 258 IMF will require flexibility to promote MOUD uptake and adherence. For instance, mobile treatment 259 units may connect PWID to healthcare and facilitate MOUD initiation and HCV and HIV testing[27]. 260 Telehealth approaches may also be helpful for PWID who own electronic devices but find travelling 261 for care difficult[28]. Long-acting MOUD also represent a powerful option to increase retention and 262 decrease the negative health effects of return to IMF use [29]. In the inpatient setting, adequate 263 pain control (using short-acting opioids) is increasingly required to manage pain and withdrawal 264 symptoms related to IMF use and prevent against-medical-advice (AMA) discharges, which are 265 currently on the rise [24,30]. Other kinds of infections affecting PWUD—such as skin and soft tissue 266 infections—have also increased in recent years, which requires further study for treatment 267 optimization in the fentanyl era [31,32]. Finally, the rise in IMF adds further evidence of the need to 268 increase point-of-care testing and HCV treatment among PWUD. Even despite ongoing substance 269 use, re-infection rates among PWID have been shown to be uncommon [33], and HCV treatment is 270 cost-effective [34].

271

272 The IMF-HCV relationship also reinforces the need for increasing preventative and primary care 273 services among PWUD. Research comparing the transmission of HCV and HIV suggests that HCV is 274 the first infection to be acquired once young people start injecting, and there is generally a brief 275 window of opportunity to prevent subsequent HIV infection [35]. Reaching individuals in this 276 window can be accomplished via increasing access to low-barrier services that PWID need to remain 277 safe (such as sterile syringes) alongside HIV and HCV testing [36]. On the West Coast of the U.S., 278 there are also early signs of a broad transition from injecting to smoking IMF, which raises important 279 considerations for blood-borne disease prevention efforts [37,38]. This shift may be helpful for 280 reducing HCV transmission if smoking supplies are less likely than syringes to transfer HCV, although 281 evidence on this topic is mixed [39]. Regardless, investing in safe smoking supplies is warranted to 282 reduce the need for sharing equipment among the growing segment of PWUD smoking IMF.

283

284 This study has several limitations. Although the HCV and HIV assays employed here were highly 285 sensitive and specific [13,14], the reliance on self-reported fentanyl use represents a limitation. 286 Some PWUD may not know they were using IMF, given limited availability of drug checking services 287 during the study period[40]. This could have caused misclassification, with a tendency to attenuate 288 associations between IMF and HIV/HCV seroconversion towards the null. Follow-up studies using 289 biological markers of fentanyl use should be conducted for confirmation. Additionally, given the 290 known shift from injecting to smoking fentanyl occurring during the follow-up period [38], statistical 291 power to detect an association between injection of IMF and HCV seroconversion may have been 292 more limited. Additionally, we did not have a sufficient sample size of HIV seroconverters to assess 293 the link between IMF and HIV, although this remains an important area for investigation. The results 294 of this study apply to a highly vulnerable population of PWID on the US-Mexico border, and further 295 study is needed to assess the generalizability to the wider North American context of IMF use.

296

### 297 Conclusions

298 The broad shift among PWUD to using synthetic opioids such as IMF represents a profound change 299 for the health risks of a broad swath of vulnerable individuals in North America. Although most

- 300 research has focused on the implications for fatal overdose rates, we provide novel evidence that
- 301 IMF use is associated with increased HCV incidence. This raises important considerations for
- 302 treatment and prevention efforts, including access to point-of-care HCV testing and treatment,
- 303 MOUD modalities and dosing, provision of harm reduction supplies and interventions to prevent
- 304 subsequent HIV acquisition. More research is needed to understand potential mechanisms
- 305 underpinning this association, as well as the role of IMF use on other infectious diseases, such as HIV
- and soft-tissue infections. 306
- 307

Baseline Characteristics <sup>a</sup>	Incident Case	Not Incident Case	Total
Sex assigned at birth (male)	79(77.5%)	199(67.2%)	278(69.8%)
Median Age (IQR)	42.5(34.0,51.0)	43.0(36.0,51.0)	43.0(35.0,51.0)
Hispanic/Latino/Mexican	68(66.7%)	198(66.9%)	266(66.8%)
Speaks English	73(71.6%)	219(74.0%)	292(73.4%)
Born in the US	59(57.8%)	145(49.0%)	204(51.3%)
San Diego Resident	68(66.7%)	200(67.6%)	268(67.3%)
Median # of years of education completed	11.0(7.0,12.0)	10.0(7.5,12.0)	10.5(7.0,12.0)
Married or Common law	15(14.7%)	61(20.6%)	76(19.1%)
Monthly income <500 USD	59(57.8%)	158(53.4%)	217(54.5%)
Homeless <sup>*b</sup>	49(48.0%)	116(39.2%)	165(41.5%)
Incarcerated*	10(9.8%)	24(8.2%)	34(8.6%)
Smokes cigarettes	75(73.5%)	222(75.0%)	297(74.6%)
Higher risk drinking	17(16.7%)	52(17.6%)	69(17.3%)
Smoked or vaped marijuana*	55(53.9%)	159(53.7%)	214(53.8%)
Used heroin*	85(83.3%)	234(79.1%)	319(80.2%)
Used methamphetamine*	88(86.3%)	245(82.8%)	333(83.7%)
Used fentanyl*	35(34.3%)	66(22.3%)	101(25.4%)
Used cocaine*	13(12.7%)	38(12.8%)	51(12.8%)
Median # of years of injection drug use	20.0(10.0,32.0)	18.0(9.0,28.0)	18.5(9.0,29.0)
Median # of injections per day (IQR)	2.5(0.3, 4.0)	2.5(0.3, 4.0)	2.5(0.3, 4.0)
Receptive needle sharing*	49(48.0%)	118(39.9%)	167(42.0%)
Distributive needle sharing*	52(51.0%)	131(44.3%)	183(46.0%)
Visited shooting galleries*	8(7.8%)	19(6.4%)	27(6.8%)
Uses hit doctor*	20(19.6%)	53(17.9%)	73(18.3%)
Experienced Overdose*	13(12.7%)	31(10.5%)	44(11.1%)
Enrolled either in a methadone or	9(8.8%)	16(5.4%)	25(6.3%)
Male having sex with male (ever) <sup>Y</sup>	17(16.7%)	47(16.0%)	64(16.2%)
Tested HIV-seropositive	12(11.8%)	23(7.8%)	35(8.8%)
Recruitment Group:			
Wave 1: SD Resident Drug Tourist	26(25.5%)	106(35.8%)	132(33.2%)
Wave 1: SD Resident non-Drug Tourist	24(23.5%)	57(19.3%)	81(20.4%)
Wave 1: TJ Resident non-Drug Tourist	34(33.3%)	96(32.4%)	130(32.7%)
Wave 2: SD Resident non-Drug Tourist	18(17.6%)	37(12.5%)	55(13.8%)

Table 1. Sample characteristics at baseline for HCV incident cases vs. not incident cases

<sup>a</sup>For the binary variables the affirmative category is presented; <sup>b</sup>Defined based on the most common


place where participants slept \*Past 6 months; <sup>Y</sup>Missing values n=2

	Used fentanyl in past 6 months	Number of incident cases	Number of people at risk	Number of person years spent at risk	,
	Total	10	363	773.36	1.29 (0.49, 2.10)
Ī	No	6	268	597.60	1.00 (0.20, 1.80)
Ī	Yes	4	95	175.76	2.28 (0.05, 4.50)

Table 2. HIV incidence density by past 6-month fentanyl use reported at baseline.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.22.24304609; this version posted March 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



axis. See supplemental table 4 for exact values. \*predictor in the past 6 months 358

#### References 359

- 360 Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. International Journal 1. 361 of Drug Policy 2017; 46:107-111.
- 362 Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic 2. 363 trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction 2023; 364 118:2477-2485.
- 365 3. Silverstein JH, Rieders MF, McMullin M, Schulman S, Zahl K. An analysis of the duration of fentanyl and 366 its metabolites in urine and saliva. Anesth Analg 1993; 76:618–621.
- 367 4. MONTERO F, BOURGOIS P, FRIEDMAN J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic: 368 Xylazine ("Trang"), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and 369 Tijuana. J Illicit Econ Dev 2022; 4:204–222.
- 370 5. Association of Illicit Fentanyl Use with Injection Risk Practices Among People who Inject Drugs | AIDS 371 and Behavior. Available at: https://link.springer.com/article/10.1007/s10461-022-03908-x. Accessed 12 372 March 2024.
- 373 6. HIV Risk Among Urban and Suburban People Who Inject Drugs: Elevated Risk Among Fentanyl and 374 Cocaine Injectors in Maryland | AIDS and Behavior. Available at: 375 https://link.springer.com/article/10.1007/s10461-021-03381-y. Accessed 12 March 2024.
- Dietze PM, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated 376 7. 377 restrictions: Anticipated consequences and initial responses. Drug Alcohol Rev 2020; 39:297–300.
- 378 8. Ciccarone D, Bourgois P. Explaining the geographical variation of HIV among injection drug users in the 379 United States. Substance use & misuse 2003; 38:2049–2063.
- 380 9. Ciccarone D, Bourgois P. Injecting drugs in tight spaces: HIV, cocaine and collinearity in the Downtown 381 Eastside, Vancouver, Canada. International Journal of Drug Policy 2016; 33:36–43.
- 382 10. The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 383 2018 | AJPH | Vol. 111 Issue 5. Available at: 384 https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306149?casa token=Mbo4Uf-385 hMzgAAAAA%3ATiMlcIIK6wQtSwEmDixHbdnqtpiKL8HAkQxzdzgs9uPOruIOJLjztmDjIsQmKAtJSA5MX3Poj 386 w. Accessed 12 March 2024.
- 387 2005-2020 Rates of Acute Hepatitis C Cases by Age | CDC. 2022. Available at: 11. 388 https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c/figure-3.4.htm. Accessed 12 389 March 2024.
- 390 12. Price JC, Brandman D. Updated Hepatitis C Virus Screening Recommendation—A Step Forward. JAMA 391 Internal Medicine 2020; 180:637-639.
- 392 13. Vetter BN, Reipold EI, Ongarello S, et al. Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis 393 C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study. The Journal of 394 Infectious Diseases 2022; 226:420-430.
- 395 Tang W, Chen W, Amini A, et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-14. 396 analysis and review of the literature. BMC Infect Dis 2017; 17:695.
- 397 15. Balan TA, Putter H. A tutorial on frailty models. Stat Methods Med Res 2020; 29:3424–3454.
- 398 16. Fleurence RL, Collins FS. A National Hepatitis C Elimination Program in the United States: A Historic 399 Opportunity. JAMA 2023; 329:1251-1252.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.22.24304609; this version posted March 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 400 17. Friedman J, Castillo FM, Bourgois P, et al. Xylazine Spreads Across the US: A Growing Component of the 401 Increasingly Synthetic and Polysubstance Overdose Crisis. 2021: 2021.09.20.21263680. Available at: 402 https://www.medrxiv.org/content/10.1101/2021.09.20.21263680v1. Accessed 2 December 2021.
- 403 18. Skaathun B. HIV-1 transmission dynamics among people who inject drugs on the US/Mexico border amid 404 COVID-19. Denver, CO: March.
- 405 19. Social Stability and HIV Risk Behavior: Evaluating the Role of Accumulated Vulnerability | AIDS and 406 Behavior. Available at: https://link.springer.com/article/10.1007/s10461-011-9882-5. Accessed 18 407 March 2024.
- 408 20. Calderón-Villarreal A, Terry B, Friedman J, et al. Deported, homeless, and into the canal: Environmental 409 structural violence in the binational Tijuana River. Social Science & Medicine 2022; 305:115044.
- 410 21. Friedman J, Calderón-Villarreal A, Adame RC, et al. An Ethnographic Assessment of COVID-19–Related 411 Changes to the Risk Environment for People Who Use Drugs in Tijuana, Mexico. Am J Public Health 2022; 412 112:S199-S205.
- 413 22. Friedman J, Syvertsen JL, Bourgois P, Bui A, Beletsky L, Pollini R. Intersectional structural vulnerability to 414 abusive policing among people who inject drugs: A mixed methods assessment in california's central 415 valley. International Journal of Drug Policy 2021; 87:102981.
- 416 23. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people 417 who inject drugs: systematic review and meta-analysis. BMJ 2012; 345:e5945.
- 418 24. Kleinman RA, Thakrar AP. Using short-acting opioids to relieve opioid withdrawal in hospital. CMAJ 2023; 419 195:E1718-E1720.
- 420 25. León-Barriera R, Zwiebel SJ, Modesto-Lowe V. A practical guide for buprenorphine initiation in the 421 primary care setting. CCJM 2023; 90:557–564.
- 422 De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use 26. 423 Disorder. Clin Drug Investig 2021; 41:425–436.
- 424 27. Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where 425 They Are | Journal of General Internal Medicine. Available at: 426 https://link.springer.com/article/10.1007/s11606-023-08142-2. Accessed 18 March 2024.
- 427 28. Bartholomew TS, Tookes HE, Chueng TA, et al. Availability of telehealth-based services at syringe 428 services programs under the COVID-19 Public Health Emergency. Harm Reduct J 2023; 20:122.
- 429 29. Maremmani I, Dematteis M, Gorzelanczyk EJ, Mugelli A, Walcher S, Torrens M. Long-Acting 430 Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder. J Clin Med 431 2023; 12:5575.
- 432 30. Kimmel SD, Kim J-H, Kalesan B, Samet JH, Walley AY, Larochelle MR. Against Medical Advice Discharges 433 in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study. 434 Clinical Infectious Diseases **2021**; 73:e2484–e2492.
- 435 Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for 31. 436 heroin-related soft tissue infections: Associations with structural market conditions. Drug and Alcohol 437 Dependence **2016**; 163:126–133.
- 438 32. Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-439 related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies 440 systematic review. BMJ Open 2021; 11:e049924.

- 33. Barocas JA. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People
  Who Inject Drugs. Clinical Infectious Diseases 2021; 72:1401–1403.
- 443 34. Barbosa C, Fraser H, Hoerger TJ, et al. Cost-Effectiveness of Scaling Up HCV Prevention and Treatment in
  444 the United States for People Who Inject Drugs. Addiction **2019**; 114:2267–2278.
- 445 35. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. | AJPH | Vol. 86 Issue 5. Available at: https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.86.5.655. Accessed 13 March 2024.
- 36. Blake A, Smith JE. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
  JAMA Network Open **2021**; 4:e2119092.
- 450 37. Kral AH, Lambdin BH, Browne EN, et al. Transition from injecting opioids to smoking fentanyl in San
  451 Francisco, California. Drug and Alcohol Dependence 2021; 227:109003.
- 45238.Eger WH, Abramovitz D, Bazzi AR, et al. Changes in injecting versus smoking heroin, fentanyl, and453methamphetamine among people who inject drugs in San Diego, California, 2020 to 2023. 2024;454:2024.02.23.24303293. Available at:

### 455 https://www.medrxiv.org/content/10.1101/2024.02.23.24303293v1. Accessed 14 March 2024.

- 456 39. De P, Roy É, Boivin J-F, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug
  457 preparation equipment: a systematic and methodological review. J Viral Hepat 2008; 15:279–292.
- 40. Bailey K, Abramovitz D, Artamonova I, et al. Drug checking in the fentanyl era: Utilization and interest
  among people who inject drugs in San Diego, California. Int J Drug Policy **2023**; 118:104086.
- 460

### 461 Acknowledgements

462 JF and DA drafted the first draft of the manuscript. DA conducted the statistical analysis. JF created 463 the graphical representations of data. All authors contributed to conceptualizing the study, revising 464 the manuscript, and agreed upon the final results. AV and CV led fieldwork and data collection. SS 465 obtained funding and supervised the study. The underlying data used in this study are protected as part of a cohort study of vulnerable individuals. Aggregated statistics may be requested from the 466 467 authors on a case-by-case basis. This work was supported by the San Diego Center for AIDS Research 468 (National Institute of Allergy and Infectious Diseases, grant P30AI036214) and the National Institute 469 on Drug Abuse (grants R01DA049644-S1, R01DA049644-02S2, K01DA043412, 3K01DA043412-04S1, 470 DP2DA049295, and T32DA023356). JRF was supported by the National Institute of General Medical 471 Sciences (grant GM008042). WHE received funding from NIDA T32 DA023356. BS received funding 472 from K01DA049665 and R03 DA57142. Authors declare no conflicts of interest.